Revlimid vs Ozempic
Side-by-side drug price comparison from Medicare Part D data
Verdict
Ozempic costs 95% less per claim than Revlimid ($685.00 vs $12786.00). Neither drug has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Ozempic at $5.0B.
| Metric | Revlimid | Ozempic |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $12,786 | $685* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.8B | $5.0B |
| Total Claims | 612,000 | 7,240,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -3.4%* | 72.5% |
| Generic Available | No | No |
| Condition | Cancer | Diabetes |
| Total Beneficiaries | 58,000 | 1,180,000 |
Ozempic costs 95% less per claim than Revlimid ($685.00 vs $12786.00). Neither drug has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Ozempic at $5.0B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Revlimid and Ozempic. What follows is the interpretation — which specific axes carry the most weight for Revlimid versus Ozempic, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.